Construction, expression and assemble of EMCV VLPs and their potency evaluation

Haixia Zhang; Shengjun Li; Jinxian Su; Xiaomei Ma; Amjad Ali; Jingying Xie; Zhongren Ma; Ruofei Feng

doi:10.1016/j.virol.2023.04.011

Construction, expression and assemble of EMCV VLPs and their potency evaluation

Virology. 2023 Jul:584:1-8. doi: 10.1016/j.virol.2023.04.011. Epub 2023 May 5.

Authors

Haixia Zhang¹, Shengjun Li², Jinxian Su³, Xiaomei Ma³, Amjad Ali², Jingying Xie⁴, Zhongren Ma¹, Ruofei Feng⁵

Affiliations

¹ Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China.
² Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China.
³ College of Life Science and Engineering, Northwest Minzu University, Lanzhou, 730030, China.
⁴ Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China; College of Life Science and Engineering, Northwest Minzu University, Lanzhou, 730030, China.
⁵ Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China. Electronic address: fengruofei@xbmu.edu.cn.

PMID: 37167793
DOI: 10.1016/j.virol.2023.04.011

Abstract

Encephalomycarditis virus (EMCV) is an essential pathogen with a broad host range and causes enormous economic losses to the pig industry worldwide. Here, we constructed and assembled the EMCV virus-like particles (VLPs) in vitro and verified high efficiency of virus protection. Results showed that the proteins auto-assembled into VLPs successfully in vitro. The animal experiments revealed that high-titer antibody production is triggered by VLPs. Meanwhile, the mice challenged with EMCV were obviously protected. The protection rate of group VLPs with the adjuvant was 75%, while that of the VLPs group was 62.5% compared to the control. These findings indicate that recombinant EMCV VLPs have a remarkable anti-EMCV effect and could be a new vaccine candidate for the control of EMCV infection.

Keywords: Auto-assembly; Encephalomycarditis virus (EMCV); Expression; Protection rate; Vaccines; Virus-like particles (VLPs).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic
Animals
Antibodies, Viral*
Antibody Formation
Mice
Swine
Vaccines, Virus-Like Particle* / genetics

Substances

Antibodies, Viral
Adjuvants, Immunologic
Vaccines, Virus-Like Particle